MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
1.140
-0.030
-2.56%
After Hours: 1.140 0 0.00% 16:10 04/09 EDT
OPEN
1.170
PREV CLOSE
1.170
HIGH
1.175
LOW
1.105
VOLUME
88.76K
TURNOVER
--
52 WEEK HIGH
1.945
52 WEEK LOW
0.9520
MARKET CAP
35.77M
P/E (TTM)
-1.0494
1D
5D
1M
3M
1Y
5Y
1D
Actinium Pharmaceuticals: Undervalued Radiopharmaceutical Play with Promising ATNM-400 Pipeline and Near‑Term Catalysts
TipRanks · 1d ago
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
PR Newswire · 3d ago
Weekly Report: what happened at ATNM last week (0330-0403)?
Weekly Report · 3d ago
Analysts Are Bullish on Top Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Actinium Pharmaceuticals (ATNM)
TipRanks · 6d ago
Actinium Pharmaceuticals Price Target Maintained With a $5.00/Share by Stephens & Co.
Dow Jones · 03/31 13:18
Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target
Benzinga · 03/31 13:08
Actinium Pharmaceuticals (ATNM) Gets a Buy from H.C. Wainwright
TipRanks · 03/31 10:39
Weekly Report: what happened at ATNM last week (0323-0327)?
Weekly Report · 03/30 10:30
More
About ATNM
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.